Revisão Revisado por pares

New Methodologies for Pharmacological Treatment Trials for Alcohol Dependence

1996; Wiley; Volume: 20; Issue: s7 Linguagem: Inglês

10.1111/j.1530-0277.1996.tb01183.x

ISSN

1530-0277

Autores

Raymond F. Anton,

Tópico(s)

Neurotransmitter Receptor Influence on Behavior

Resumo

Alcoholism: Clinical and Experimental ResearchVolume 20, Issue s7 p. 3A-9A New Methodologies for Pharmacological Treatment Trials for Alcohol Dependence Raymond F. Anton, Corresponding Author Raymond F. Anton Institute of Psychiatry, Medical University of South Carolina, Charleston, South Carolina.Reprint requests: Raymond F. Anton, M.D., Center for Drug and Alcohol Programs, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC 29425-0742.Search for more papers by this author Raymond F. Anton, Corresponding Author Raymond F. Anton Institute of Psychiatry, Medical University of South Carolina, Charleston, South Carolina.Reprint requests: Raymond F. Anton, M.D., Center for Drug and Alcohol Programs, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC 29425-0742.Search for more papers by this author First published: October 1996 https://doi.org/10.1111/j.1530-0277.1996.tb01183.xCitations: 34 Presented, in part, at the Research Society on Alcoholism Annual Meeting, June 23, 1994, Maui, HI. This work was supported by the National Institute on Alcohol Abuse and Alcoholism Grant lROlAA09568. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Linnoila M, Fawcett J, Fuller RK, Harford TC, Martin PB, Meyer RE, Romach MK, Sellers EM: Evaluation of pharmacologic treatments for alcohol abuse, dependence, and their complications, in RF Prien, DS Robinson, (eds): Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines. New York , Raven Press, 1994, pp 625–649. 2 Grant BF, Harford TC, Chou P, Pickering R, Dawson DA, Stinson FS, Noble J: Prevalence of DSM-III-R alcohol abuse and dependence: United States, 1988 (Epidemiologic Bulletin no. 27). Alcohol Health Respondent World 15: 91–96, 1991. 3 Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK: Comorbidity of mental disorders with alcohol and other drug abuse: Results from the epidemiologic catchment area (ECA) study. JAMA 264: 2511–2518, 1990. 4 Eckardt MJ, Harford TC, Kaelber CT, Parker ES, Rosenthal LS, Ryback RS, Salmoiraghi GC, Vanderveen E, Warren KR: Health hazards associated with alcohol consumption. JAMA 246: 648–666, 1981. 5 Stinson FS, Williams GD, Bertolucci D, Noble J: Alcohol-related morbidity, 1979–1984 (Epidemiologic Bulletin No. 14). Alcohol Health Res World 1156–61, 1987. 6 Centers for Disease Control: Alcohol-related mortality and years of potential life lost-United States, 1987. MMWR 39: 173–178, 1990. 7 Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, James KE, Lacoursiere RB, Lee KK, Lowenstam I, Maany I, Neiderhiser D, Nocks JJ, Shaw S: Disulfiram treatment of alcoholism: A Veterans Administration Cooperative Study. JAMA 256: 1449–1455. 8 Anton RF: Medications for treating alcoholism. Alcohol Health Res World 18: 265–271, 1994. 9 Anton RF: New direction in the pharmacotherapy of alcoholism. Psychiatr Ann 25: 353–362, 1995. 10 Kranzler HR, Anton RF: Implications of recent neuropharmacologic research for understanding the etiology and development of alcoholism. J Consult Clin Psychol 62: 1116–1126, 1994. 11 Kranzler HR, Mason BJ, Pettinati H, Anton RF: Methodological issues in clinical trials with alcoholics, in M Hertzman, D Feltner, (eds): Clinical Trials of CNS Drugs. New York , New York University Press (in press). 12 Moak DH, Anton RF, Malcolm R, Randall CL, Brady K: Alcoholic subjects with anxiety disorder: Characteristics of completers and noncompleters in a pharmacologic study. Am J Addict 2: 39–47, 1993. 13 Taylor WC, Obitz FW, Reich JW: Experimental bias resulting from using volunteers in alcoholism research. J Stud Alcohol 43: 240–251, 1982. 14 Strohmetz DB, Alterman AI, Walter D: Subject selection bias in alcoholics volunteering for a treatment study. Alcohol Clin Exp Respondent 14: 736–738, 1990. 15 McLellan AT, Luborsky L, Woody GE, O'Brien CP, Druley KA: Predicting response to alcohol and drug abuse treatments: Role of psychiatric severity. Arch Gen Psychiatry 40: 620–625, 1983. 16 Ross HE, Glaser FB, Germanson T: The prevalence of psychiatric disorders in patients with alcohol and other drug problems. Arch Gen Psychiatry 45: 1023–1031, 1988. 17 Dorus W, Ostrow DG, Anton R, Cushman P, Collins JF, Schaefer M, Charles HL, Desai P, Hayashida M, Malkerneker U, Willenbring M, Fiscella R, Sather MR: Lithium treatment of depressed and nondepressed alcoholics. JAMA 262: 1646–1652, 1989. 18 Fawcett J, Clark DC, Aagesen CA, Pisani VD, Tilkin JM, Sellers D, McGuire M, Gibbons RD: A double-blind, placebo-controlled trial of lithium carbonate therapy for alcoholism. Arch Gen Psychiatry 44: 248–256, 1987. 19 De la Fuente JR, Morse RM, Niven NG, Ilstrup DM: A controlled study of lithium carbonate in the treatment of alcoholism. Mayo Clin Proc 64: 177–180, 1989. 20 Merry J, Reynolds CM, Bailey J, Coppen A: Prophylactic treatment of alcoholism by lithium carbonate. Lancet 1: 481–482, 1976. 21 Kline NS, Wren JC, Cooper TB, Varga E, Canal O: Evaluation of lithium therapy in chronic and periodic alcoholism. Am J Med Sci 268: 15–20, 1974. 22 Freiman JA, Chalmers TC, Smith H Jr, Kuebler RR: The importance of beta, the type II error and sample size in the design and interpretation of the randomized controlled trial: Survey of 71 “negative” trials. N Engl J Med 299: 690–694, 1978. 23 Anton RF: New methodologies in clinical pharmacologic trials of alcoholism. Presented at the Research Society on Alcoholism Annual Meeting, June 23, 1994, Maui , HI . 24 Spriet A, Simon P: Methodology of Clinical Drug Trials translated by (Edelstein R, Weintraub M). Basel , Karger Publishers, 1985, pp 127–135. 25 Spilker B: Guide to Clinical Trials. New York , Raven Press, 1991. 26 Young LM, Haakenson CM, Lee KK, Van Eeckhout JR: Riboflavin use as a drug marker in veterans administration cooperative studies. Controlled Clin Trials 5: 497–504, 1984. 27 Lambert WE, Cammaert PM, De Leenheer AP: Liquid-chromatographic measurement of riboflavin in serum and urine with isoriboflavin as internal standard. Clin Chem 31: 1371–1373, 1985. 28 Babiker IE, Cooke PR, Gillett MG: How useful is riboflavin as a tracer of medication compliance J Behav Med 12: 25–38, 1989. 29 Malcolm R, Anton RF, Randall CL, Johnston A, Brady K, Thevos A: A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res 16: 1007–1013, 1992. 30 Kranzler HR, Burleson JA, Del Boca FK, Babor TF, Korner P, Brown J, Bohn MJ: Buspirone treatment of anxious alcoholics: A placebocontrolled trial. Arch Gen Psychiatry 51: 720–731, 1994. 31 Helzer JE, Robins LN, Taylor JR, Carey K, Miller RH, Combs-Orme T, Farmer A: The extent of long-term moderate drinking among alcoholics discharged from medical and psychiatric facilities. N Engl J Med 312: 1678–1682, 1985. 32 Polich JM, Armor DJ, Braiker HB: Stability and change in drinking patterns, in The Course of Alcoholism; Four Years After Treatment. New York , John Wiley and Sons, 1981, pp 159–200. 33 Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP: Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49: 876–880, 1992. 34 O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. Arch Gen Psychiatry 49: 881–887, 1992. 35 Ludwig AM: Understanding the Alcoholic's Mind. New York , Oxford University Press, 1988, pp 33–48. 36 O'Connor PG, Gottlieb LD, Kraus ML, Segal SR, Horwitz RI: Social and clinical features as predictors of outcome in outpatient alcohol withdrawal. J Gen Intern Med 6: 312–316, 1991. 37 Modell JG, Glaser FB, Cyr L, Mountz JM: Obsessive and compulsive characteristics of craving for alcohol in alcohol abuse and dependence. Alcohol Clin Exp Res 16: 272–274, 1992. 38 Modell JG, Glaser FB, Mountz JM, Schmaltz S, Cyr L: Obsessive and compulsive characteristics of alcohol abuse and dependence: Quantification by a newly developed questionnaire. Alcohol Clin Exp Respondent 16: 266–271, 1992. 39 Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS: The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46: 1006–1011, 1989. 40 Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS: The Yale-Brown Obsessive Compulsive Scale. 11. Validity. Arch Gen Psychiatry 46: 1012–1016, 1989. 41 Anton RF, Moak DH, Catham P: The obsessive compulsive drinking scale: A self rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res 19: 92–99, 1995. 42 Anton RF, Moak DH, Latham PK: The Obsessive Compulsive Drinking Scale (OCDS): A new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry 53: 225–231, 1996. 43 Orrego H, Blendis LM, Blake JE, Kapur BM, Israel Y: Reliability of assessment of alcohol intake based on personal interviews in a liver clinic. Lancet 1: 1354–1356, 1979. 44 Sobell MB, Sobell LC, VanderSpek R: Relationships among clinical judgment, self-report, and breath-analysis measures of intoxication in alcoholics. J Consult Clin Psychol 47: 204–206, 1979. 45 Fuller RK, Lee KK, Gordis E: Validity of self-report in alcoholism research: Results of a Veterans Administration Cooperative Study. Alcohol Clin Exp Res 12: 201–205, 1988. 46 Rosman AS, Lieber CS: Biochemical markers of alcohol consumption. Alcohol Health Res World 14: 210–218, 1990. 47 Allen JP, Litten RZ, Anton RF. Measures of alcohol consumption in perspective, in RZ Litten, JP Allen, (eds): Measuring Alcohol Consumption: Psychosocial and Biologic Methods. Totowa , NJ , Humana Press, 1992. 48 Mihas AA, Tavassoli M: Laboratory markers of ethanol intake and abuse: A critical appraisal. Am J Med Sci 303: 415–428, 1992. 49 Irwin M, Baird S, Smith TL, Schuckit M: Use of laboratory tests to monitor heavy drinking by alcoholic men discharged from a treatment program. Am J Psychiatry 145: 595–599, 1988. 50 Stibler H: Carbohydrate-deficient transferrin in serum: A new marker of potentially harmful alcohol consumption reviewed. Clin Chem 37: 2029–2037, 1991. 51 Allen JP, Litten RZ, Anton RF, Cross GM: Carbohydrate-deficient transferrin as a measure of immoderate drinking: Remaining issues. Alcohol Clin Exp Res 18: 799–812, 1994. 52 Anton RF, Moak DH: Carbohydrate-deficient transferrin and γ-glutamyltransferase as markers of heavy alcohol consumption: Gender differences. Alcohol Clin Exp Res 18: 747–754, 1994. 53 Stibler H, Borg S, Joustra M: Micro anion exchange chromatography of carbohydrate-deficient transferrin in serum in relation to alcohol consumption (Swedish patent 8400587–5). Alcohol Clin Exp Res 10: 535–544, 1986. 54 Xin Y, Rosman AS, Lasker JM, Lieber CS: Measurement of carbohydrate-deficient transferrin by isoelectric focusing/western blotting and by micro anion-exchange chromatography/radioimmunoassay: Comparison of diagnostic accuracy. Alcohol Alcohol 27: 425–433, 1992. 55 Anton R, Bean P: Comparison of two methods of carbohydrate-deficient transferrin (CDT) measurement in inpatient alcoholics and healthy controls. Clin Chem 40: 364–368, 1994. 56 Anton RF, Moak DH, Latham PK: Carbohydrate-deficient transferrin as an indicator of drinking status. Alcohol Clin Exp Res 20: 841–846, 1996. Citing Literature Volume20, Issues7October 1996Pages 3A-9A ReferencesRelatedInformation

Referência(s)